An experimental GLP-1 pill from Eli Lilly just outperformed Novo Nordisk’s oral semaglutide. In a new study, Eli Lilly’s oral pill, orforglipron, helped lower diabetes patients blood sugar more and weight better than Novo Nordisk’s (sold under brand names Ozempic, Rybelsus, and Wegovy).

According to a Sept. 16 press release, three separate doses of the new drug (6 mg, 12 mg, and 36 mg) demonstrated “significant improvements” in body weight reduction compared to a placebo at 72 weeks. “Obesity is a complex, global health challenge — and patients need treatment options that are both effective and easy to integrate into everyday life,” Sean Wharton, M.D., director at Wharton Medical Clinic and lead investigator, said in the release.

Wharton continued, “In this Phase 3 study, orforglipron de

See Full Page